Vaccination in Patients with Cardiovascular Disease: A Case-Based Approach and Contemporary Review

Area of Science:

• Cardiology
• Public Health
• Immunology

Background:

• Individuals with cardiovascular disease (CVD) face higher risks of severe outcomes from infections like influenza, SARS-CoV-2, RSV, VZV, and pneumococcal disease.
• These infections can trigger adverse cardiovascular events, including ischemic events and myocarditis, worsening patient prognosis.
• Vaccination is a critical preventative measure for this vulnerable population.

Purpose of the Study:

• To review the benefits of vaccination in patients with cardiovascular disease.
• To highlight the suboptimal vaccination rates in this demographic.
• To identify strategies for improving vaccine uptake and addressing vaccine hesitancy.

Main Methods:

• Review of randomized controlled trials and observational/cohort studies on vaccine efficacy in CVD patients.
• Analysis of data from influenza, SARS-CoV-2, RSV, VZV, and pneumococcal vaccination studies.
• Examination of factors contributing to low vaccination uptake and potential interventions.

Main Results:

• Influenza vaccination demonstrated a reduction in major adverse cardiovascular events and mortality in CVD patients.
• Observational data supports the benefits of vaccination against SARS-CoV-2, RSV, VZV, and pneumococcal disease in those with CV comorbidities.
• Despite proven benefits and recommendations, vaccination rates among CVD patients remain low due to information gaps, access issues, and mistrust.

Conclusions:

• Vaccination is essential for reducing morbidity and mortality in cardiovascular disease patients.
• Addressing vaccine hesitancy through improved communication, patient education, and enhanced access is crucial.
• Healthcare providers, especially cardiologists, must actively promote vaccination during clinical encounters to improve patient outcomes.